Chicago Center on Musculoskeletal Pain (C-COMP) (Overall Application)
芝加哥肌肉骨骼疼痛中心 (C-COMP)(整体申请)
基本信息
- 批准号:10488591
- 负责人:
- 金额:$ 77.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-14 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAffectAnalgesicsAnimal ModelAreaArthritisBehavioralBehavioral AssayBioinformaticsChicagoChronicClinicalCommunicationCommunitiesConsultationsCustomDiseaseElectrophysiology (science)EnvironmentEquipmentFosteringFundingGeographyGoalsGrantHumanInfrastructureInterdisciplinary StudyInvestigationKnowledgeLeadershipMusculoskeletalMusculoskeletal DiseasesMusculoskeletal PainMusculoskeletal SystemNeurobiologyNeurosciencesNon-Steroidal Anti-Inflammatory AgentsOpioidPainPain ResearchPatientsPharmaceutical PreparationsPhysiologyPopulationPostdoctoral FellowProtocols documentationResearchResearch InfrastructureResearch PersonnelResearch SupportResearch TrainingResourcesRheumatismScientistServicesSourceTechniquesTechnologyTestingTimeTissuesTrainingTraining and EducationTranslational ResearchTranslationsbasebehavior testcareerchronic musculoskeletal painchronic paincollaborative environmentdisabilityin vivo calcium imaginginnovationmultidisciplinaryneuronal circuitrynew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsopioid abuseoptogeneticsoutreachpain reliefpreventprogramsside effecttesting accesstranscriptomicsweb site
项目摘要
Project summary
We seek to establish a new resource-based Center to foster and support research and training aimed at
understanding the mechanisms underlying pain associated with musculoskeletal (MSK) and rheumatic diseases,
with the ultimate goal of better managing and preventing it. One third of the world’s population is affected by
chronic pain, and the MSK system is the most prevalent source of pain and disability. Currently available
analgesic drugs act on a limited number of targets, and they do not provide sustained pain relief and their chronic
use is associated with serious adverse effects. One of the major obstacles in identifying safe and efficacious
drugs for producing pain relief is our general lack of understanding of the mechanisms underlying MSK pain, and
how these mechanisms may overlap or differ between different types of rheumatic and MSK diseases. The
Chicago Center on Musculoskeletal Pain (C-COMP) will address this need in a timely and unique manner,
capitalizing on the world class expertise that is available to us in the areas of MSK research, pain and
neurobiology to achieve the following broad long-term goals: (1) To integrate basic, translational and clinical
expertise in a multidisciplinary Center which will provide the leadership and resources for promoting MSK pain
research; (2) To enhance the research environment for the MSK research community by providing access to
world-class expertise and state-of-the-art resources, technologies, and infrastructure for studying pain; (3) To
promote interdisciplinary research between the MSK research field and the field of pain/neuroscience; (4) To
expand the MSK pain research community by attracting early career as well as established researchers into this
area of study. We envision three Cores operating in support of these overall goals. The Administrative Core A
(PI: A.M. Malfait; co-director: J.J. Jacobs) will provide leadership, maintain effective communication, partner with
related Centers to stimulate human translation of findings, and implement a dynamic enrichment program. The
Behavioral Resource Core B (PI: R.E. Miller; co-director: D.R. Sumner) will provide a centralized resource to
facilitate behavioral assays in a broad array of animal models of rheumatic and MSK diseases, including training
for behavioral tests, access to customized protocols, equipment, and space to perform testing, a consultation
service and a customized, full-service option for behavioral testing. The Neurobiology Core C (PI: RJ Miller; co-
director: D.R. Sumner) will offer state-of-the-art techniques for assessment and manipulation of neuronal circuitry
involved in pain physiology, such as in vivo calcium imaging, electrophysiology, chemo/optogenetics,
transcriptomics/bioinformatics and neuroanatomical techniques. This will allow the Center’s research community
to engage in cutting-edge investigations of the mechanisms of pain in animal models of MSK disease. In
summary, C-COMP will provide (1) unique resources and infrastructure for supporting high-quality externally
funded research and (2) pilot funding, education, and training in a multidisciplinary and collaborative fashion.
This integrated approach is expected to accelerate research in pain associated with MSK and rheumatic disease.
项目概要
我们寻求建立一个新的以资源为基础的中心,以促进和支持旨在
了解与肌肉骨骼 (MSK) 和风湿性疾病相关的疼痛的机制,
最终目标是更好地管理和预防世界三分之一的人口受到影响。
慢性疼痛,MSK 系统是目前最常见的疼痛和残疾来源。
镇痛药物作用于有限的目标,并且不能提供持续的疼痛缓解,并且其慢性疼痛
使用与严重的不良反应有关,这是确定安全和有效的主要障碍之一。
之所以能够缓解疼痛,是因为我们的药物普遍缺乏对 MSK 疼痛背后机制的了解,并且
这些机制在不同类型的风湿病和 MSK 疾病之间如何重叠或不同。
芝加哥肌肉骨骼疼痛中心 (C-COMP) 将及时、独特地满足这一需求,
利用我们在 MSK 斯隆研究、疼痛和疾病领域的世界级专业知识
神经生物学以实现以下广泛的长期目标:(1)整合基础、转化和临床
多学科中心的专业知识将为促进 MSK 斯隆疼痛提供领导力和资源
研究;(2) 通过提供以下途径来改善 MSK 研究界的研究环境:
(3) 至
促进 MSK 研究领域与疼痛/神经科学领域之间的跨学科研究; (4)
通过吸引早期职业生涯以及成熟的研究人员加入该领域,扩大 MSK 斯隆疼痛研究社区
我们设想三个核心来支持这些总体目标。
(PI:A.M. Malfait;联合主任:J.J. Jacobs)将提供领导,保持有效沟通,与
相关中心刺激人类对研究结果的翻译,并实施动态丰富计划。
行为资源核心 B(PI:R.E. Miller;联合主任:D.R. Sumner)将提供集中资源
促进多种风湿病和 MSK 疾病动物模型的行为测定,包括训练
对于行为测试,获得定制的协议、设备和空间来执行测试、咨询
神经生物学核心 C 服务和定制的全方位服务选项(PI:RJ Miller;合作)
导演:D.R. Sumner)将提供最先进的神经回路评估和操作技术
涉及疼痛生理学,例如体内钙成像、电生理学、化学/光遗传学、
这将使该中心的研究团体能够利用转录组学/生物信息学和神经解剖学技术。
从事 MSK 疾病动物模型疼痛机制的前沿研究。
总结一下,C-COMP将提供(1)独特的资源和基础设施来支持高质量的外部
以多学科和协作的方式资助研究和(2)试点资助、教育和培训。
这种综合方法预计将加速与 MSK 和风湿病相关的疼痛研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anne-Marie Malfait其他文献
Anne-Marie Malfait的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anne-Marie Malfait', 18)}}的其他基金
Chicago Center on Musculoskeletal Pain (C-COMP) (Overall Application)
芝加哥肌肉骨骼疼痛中心 (C-COMP)(整体申请)
- 批准号:
10676988 - 财政年份:2021
- 资助金额:
$ 77.01万 - 项目类别:
Molecular Pathways of Pain Generation in Osteoarthritis
骨关节炎疼痛产生的分子途径
- 批准号:
8214516 - 财政年份:2011
- 资助金额:
$ 77.01万 - 项目类别:
Molecular Pathways of Pain Generation in Osteoarthritis
骨关节炎疼痛产生的分子途径
- 批准号:
10665705 - 财政年份:2011
- 资助金额:
$ 77.01万 - 项目类别:
相似国自然基金
儿童药品不良反应主动监测中时序处理策略的方法学研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 77.01万 - 项目类别:
Developing and Evaluating a Positive Valence Treatment for Alcohol Use Disorder with Anxiety or Depression
开发和评估治疗伴有焦虑或抑郁的酒精使用障碍的正价疗法
- 批准号:
10596013 - 财政年份:2023
- 资助金额:
$ 77.01万 - 项目类别:
Impact of Body Composition and Related Inflammatory and Immune States on Prognosis of Non-Muscle Invasive Bladder Cancer
身体成分及相关炎症和免疫状态对非肌肉浸润性膀胱癌预后的影响
- 批准号:
10674401 - 财政年份:2023
- 资助金额:
$ 77.01万 - 项目类别:
Signaling and metabolic functions of nSMase-2 in hepatic steatosis and onset of insulin resistance
nSMase-2 在肝脂肪变性和胰岛素抵抗发作中的信号传导和代谢功能
- 批准号:
10735117 - 财政年份:2023
- 资助金额:
$ 77.01万 - 项目类别: